Nova Eye Medical Reports 26% Sales Growth, Expects Positive EBITDA In FY27
EYE: $0.150 +0.00% · MC: $43M
Nova Eye Medical reported FY26 sales growth of approximately 26% and positive EBITDA in the second half, compared with a loss in the prior-year half; its full-year EBITDA loss narrowed substantially. The company expects positive EBITDA in FY27 while maintaining strong sales growth, and says it has started the year with continued sales momentum and reaffirmed growth guidance. At its AGM, shareholders rejected the remuneration report, while director election resolutions were carried.

Comments